Brainstorm cell therapeutics announces strategic realignment prioritizing nurown® for the treatment of als

-  resource consumption will be reduced by 50% to accelerate als development -  plans underway for registrational phase 3b u.s. clinical trial for nurown in als new york , oct. 24, 2023 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced a strategic realignment to enable accelerated development of nurown® for the treatment of amyotrophic lateral sclerosis (als). this realignment is designed to 1) support the company plans to conduct a double-blind, placebo-controlled phase 3b u.s. clinical trial for nurown in als with an open-label extension and 2) continue to publish data from nurown's phase 3 clinical trial on: biomarkers, long-term safety and survival, and the expanded access program, providing transparency around nurown data and progressing als drug development.
BCLI Ratings Summary
BCLI Quant Ranking